Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 12.19
    2006

    Addex begins Phase IIa Proof of Concept Study on ADX10059 for Treatment of Acute Anxiety

  • 09.19
    2006

    Addex Pharmaceuticals Raises CHF40 million-SR One and Roche Venture Funds invest in Series C Private Financing

  • 08.30
    2006

    Addex commences Phase II clinical trials programme with ADX10059

  • 09.22
    2005

    Addex Pharmaceuticals Initiates Phase I Trials with ADX10059, a novel compound intended for Anxiety and Migraine

  • 01.26
    2005

    Addex Pharmaceuticals named by tornado insider among europe's top 100 private tech companies

  • 01.17
    2005

    Addex Pharmaceuticals enters into Collaboration with Ortho-McNeil Pharmaceutical to Develop Novel Treatments for Anxiety, Depression, Schizophrenia and Alzheimer's disease

  • 11.11
    2004

    Addex Pharmaceuticals lauréate du Prix de la Jeune Industrie de Genève

  • 05.17
    2004

    Addex Pharmaceuticals Completes Largest ever European Biotech Series B Fund Raising

  • 12.10
    2003

    Addex Pharmaceuticals Signs Three year Clinical Development Partnership with Fulcrum Pharma Plc

  • 12.18
    2002

    CeNeS Announces Phase II Drug Deal with Addex Pharmaceuticals

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics